Investor Overview – Zai Lab Limited

Corporate Profile

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

INVESTOR HIGHLIGHTS

Corporate Mission

Learn More

Investor Presentation

Learn More

Our Pipeline

Learn More

Stock Quote

2023年 6月 07日 7:26 AM EDT

Jun 7, 2023 7:26 AM EDT

Volume
Day Low/High /
52 - Week Low/High /

2023年 6月 07日 7:26 AM EDT

Jun 7, 2023 7:26 AM EDT

Volume
Day Low/High /
52 - Week Low/High /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

2023年 6月 07日 7:26 AM EDT

Jun 7, 2023 7:26 AM EDT

Volume
Day Low/High /
52 - Week Low/High /

2023年 6月 07日 7:26 AM EDT

Jun 7, 2023 7:26 AM EDT

Volume
Day Low/High /
52 - Week Low/High /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Zai Lab Limited effected a one-to-ten share subdivision effective as of March 30, 2022 (the “Share Subdivision”). Pursuant to the Share Subdivision, each Ordinary Share of the Company was subdivided into ten ordinary shares, and each American Depositary Share (ADS) of the Company now represents ten Ordinary Shares of the Company. If you hold Ordinary Shares of the Company, such as those traded on the Hong Kong Stock Exchange, the number of Ordinary Shares that you held before the Share Subdivision has increased tenfold as a result of the Share Subdivision (therefore if you held 100 Ordinary Shares prior to the Share Subdivision, you now hold 1,000 Ordinary Shares). If you hold ADSs of the Company, such as traded through NASDAQ, the number of ADSs that you held before the Share Subdivision did not change as a result of the Share Subdivision (therefore if you held 100 ADSs prior to the Share Subdivision, you continue to hold 100 ADSs).

Recent Press Releases

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Zai Lab Announces Participation in June Investor Conferences

Investor & Media Contacts

Investor Inquiries

Christine Chiou, SVP, Head of Investor Relations
+1 (917) 886-6929
christine.chiou1@zailaboratory.com

Lina Zhang, Executive Director, Corporate Strategy and Capital Markets
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media Inquiries
Shaun Maccoun, Executive Director, Global Communications
+1 (415) 317-7255
shaun.maccoun@zailaboratory.com

Xiaoyu Chen, Executive Director, Regional Communications
+86 185 0015 5011
xiaoyu.chen@zailaboratory.com